ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC

Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news